Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents

[1]  Z. Szallasi,et al.  Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents , 2019, Genome Biology.

[2]  L. Byers,et al.  PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers , 2019, Clinical Cancer Research.

[3]  Ville Mustonen,et al.  The repertoire of mutational signatures in human cancer , 2018, Nature.

[4]  I. Faraoni,et al.  Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors , 2018, Cancers.

[5]  B. Gilks,et al.  Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes , 2018, British Journal of Cancer.

[6]  Rui Bi,et al.  The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. , 2018, Journal of the National Cancer Institute.

[7]  Maryam Clausen,et al.  Decoding non-random mutational signatures at Cas9 targeted sites , 2018, Nucleic acids research.

[8]  A. Chinnaiyan,et al.  Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer , 2018, Cell.

[9]  Edwin Cuppen,et al.  MutationalPatterns: comprehensive genome-wide analysis of mutational processes , 2016, Genome Medicine.

[10]  Monideepa Roy,et al.  Role of BRCA Mutations in the Modulation of Response to Platinum Therapy , 2018, Front. Oncol..

[11]  S. Park,et al.  Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.

[12]  L. Zou,et al.  MRE11 and EXO1 nucleases degrade reversed forks and elicit MUS81-dependent fork rescue in BRCA2-deficient cells , 2017, Nature Communications.

[13]  J. Reis-Filho,et al.  Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes , 2017, Nature Communications.

[14]  Alberto Ciccia,et al.  Smarcal1-Mediated Fork Reversal Triggers Mre11-Dependent Degradation of Nascent DNA in the Absence of Brca2 and Stable Rad51 Nucleofilaments , 2017, Molecular cell.

[15]  E. Lander,et al.  A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer , 2017, Nature Genetics.

[16]  Alexander Gutin,et al.  Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women. , 2017, JCO precision oncology.

[17]  E. Birney,et al.  HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures , 2017, Nature Medicine.

[18]  Yves Pommier,et al.  A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress , 2017, Nature Medicine.

[19]  Z. Szallasi,et al.  Fast and accurate mutation detection in whole genome sequences of multiple isogenic samples with IsoMut , 2017, BMC Bioinformatics.

[20]  I Csabai,et al.  Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions , 2016, Oncogene.

[21]  Masafumi Nakamura,et al.  BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer , 2016, PloS one.

[22]  Ignace Vergote,et al.  Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. , 2016, The New England journal of medicine.

[23]  Andrew H. Beck,et al.  A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma , 2016, Cancer Epidemiology, Biomarkers & Prevention.

[24]  Gábor E. Tusnády,et al.  A comprehensive survey of the mutagenic impact of common cancer cytotoxics , 2016, Genome Biology.

[25]  David C. Jones,et al.  Landscape of somatic mutations in 560 breast cancer whole genome sequences , 2016, Nature.

[26]  Gad Getz,et al.  Somatic ERCC2 Mutations Are Associated with a Distinct Genomic Signature in Urothelial Tumors , 2016, Nature Genetics.

[27]  A. Escargueil,et al.  Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair , 2016, Oncotarget.

[28]  Z. Szallasi,et al.  Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer , 2016, Clinical Cancer Research.

[29]  B. Taylor,et al.  deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution , 2016, Genome Biology.

[30]  G. Shapiro,et al.  Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. , 2015, Cancer discovery.

[31]  Lara E Sucheston-Campbell,et al.  Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  K. Rogers,et al.  The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers , 2015, Hereditary cancer in clinical practice.

[33]  E. Egelman,et al.  Rad51 Paralogs Remodel Pre-synaptic Rad51 Filaments to Stimulate Homologous Recombination , 2015, Cell.

[34]  C. Wang,et al.  Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  C. Deng,et al.  Damage-induced BRCA1 phosphorylation by Chk2 contributes to the timing of end resection , 2015, Cell cycle.

[36]  D. Branzei,et al.  High levels of BRC4 induced by a Tet-On 3G system suppress DNA repair and impair cell proliferation in vertebrate cells , 2014, DNA repair.

[37]  Gábor E. Tusnády,et al.  The Genome of the Chicken DT40 Bursal Lymphoma Cell Line , 2014, G3: Genes, Genomes, Genetics.

[38]  Nazneen Rahman,et al.  Breast-cancer risk in families with mutations in PALB2. , 2014, The New England journal of medicine.

[39]  Alexander M. Metcalf,et al.  Mismatch repair deficiency endows tumors with a unique mutation signature and sensitivity to DNA double-strand breaks , 2014, eLife.

[40]  S. Lees-Miller,et al.  Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines , 2014, Cell cycle.

[41]  Björn Usadel,et al.  Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..

[42]  H. Kurumizaka,et al.  Compensatory functions and interdependency of the DNA-binding domain of BRCA2 with the BRCA1-PALB2-BRCA2 complex. , 2014, Cancer research.

[43]  Sheena M. Scroggins,et al.  Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas , 2013, Clinical Cancer Research.

[44]  David A. Scott,et al.  Genome engineering using the CRISPR-Cas9 system , 2013, Nature Protocols.

[45]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[46]  S. Powell,et al.  Molecular Pathways: Understanding the Role of Rad52 in Homologous Recombination for Therapeutic Advancement , 2012, Clinical Cancer Research.

[47]  J. George,et al.  BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  A. Børresen-Dale,et al.  Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.

[49]  Steven Salzberg,et al.  BIOINFORMATICS ORIGINAL PAPER , 2004 .

[50]  Michael C. Rusch,et al.  CREST maps somatic structural variation in cancer genomes with base-pair resolution , 2011, Nature Methods.

[51]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[52]  G. Mills,et al.  Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  Feng Zhang,et al.  PALB2 Links BRCA1 and BRCA2 in the DNA-Damage Response , 2009, Current Biology.

[54]  W. Lu,et al.  Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins , 2008, Molecular Cancer Therapeutics.

[55]  G. Zachos,et al.  Chk2 is required for optimal mitotic delay in response to irradiation-induced DNA damage incurred in G2 phase , 2008, Oncogene.

[56]  Olufunmilayo I. Olopade,et al.  Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations , 2007, Nature Reviews Cancer.

[57]  Wolf-Dietrich Heyer,et al.  Rad54: the Swiss Army knife of homologous recombination? , 2006, Nucleic acids research.

[58]  N. Galjart,et al.  Differential Contributions of Mammalian Rad54 Paralogs to Recombination, DNA Damage Repair, and Meiosis , 2006, Molecular and Cellular Biology.

[59]  Ji-Hoon Lee,et al.  ATM Activation by DNA Double-Strand Breaks Through the Mre11-Rad50-Nbs1 Complex , 2005, Science.

[60]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[61]  D. Schild,et al.  Mutants of the Five Rad51 Paralogs Recombinational Repair in Knockout Chromosome Instability and Defective , 2022 .

[62]  I. Longden,et al.  EMBOSS: the European Molecular Biology Open Software Suite. , 2000, Trends in genetics : TIG.

[63]  K. Yoshioka,et al.  Disruption of ATM in p53-null cells causes multiple functional abnormalities in cellular response to ionizing radiation , 1999, Oncogene.

[64]  A. Bowcock,et al.  The C-terminal (BRCT) Domains of BRCA1 Interact in Vivo with CtIP, a Protein Implicated in the CtBP Pathway of Transcriptional Repression* , 1998, The Journal of Biological Chemistry.

[65]  Yuko Yamaguchi-Iwai,et al.  Reduced X-Ray Resistance and Homologous Recombination Frequencies in a RAD54−/− Mutant of the Chicken DT40 Cell Line , 1997, Cell.

[66]  Anne M. Bowcock,et al.  Identification of a RING protein that can interact in vivo with the BRCA1 gene product , 1996, Nature Genetics.